- Home
- DLY vs TYRA Comparison
DLY vs TYRA Comparison
Compare DLY & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- TYRA
- Stock Information
- Founded
- DLY 2019
- TYRA 2018
- Country
- DLY United States
- TYRA United States
- Employees
- DLY N/A
- TYRA N/A
- Industry
- DLY Investment Managers
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- TYRA Health Care
- Exchange
- DLY Nasdaq
- TYRA Nasdaq
- Market Cap
- DLY 759.6M
- TYRA 608.9M
- IPO Year
- DLY N/A
- TYRA 2021
- Fundamental
- Price
- DLY $15.47
- TYRA $10.45
- Analyst Decision
- DLY
- TYRA Strong Buy
- Analyst Count
- DLY 0
- TYRA 7
- Target Price
- DLY N/A
- TYRA $30.86
- AVG Volume (30 Days)
- DLY 215.9K
- TYRA 215.6K
- Earning Date
- DLY 01-01-0001
- TYRA 08-19-2025
- Dividend Yield
- DLY 8.93%
- TYRA N/A
- EPS Growth
- DLY N/A
- TYRA N/A
- EPS
- DLY N/A
- TYRA N/A
- Revenue
- DLY N/A
- TYRA N/A
- Revenue This Year
- DLY N/A
- TYRA N/A
- Revenue Next Year
- DLY N/A
- TYRA N/A
- P/E Ratio
- DLY N/A
- TYRA N/A
- Revenue Growth
- DLY N/A
- TYRA N/A
- 52 Week Low
- DLY $13.26
- TYRA $6.42
- 52 Week High
- DLY $15.95
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- DLY 55.26
- TYRA 48.16
- Support Level
- DLY $15.38
- TYRA $10.00
- Resistance Level
- DLY $15.49
- TYRA $11.72
- Average True Range (ATR)
- DLY 0.07
- TYRA 0.67
- MACD
- DLY 0.02
- TYRA -0.06
- Stochastic Oscillator
- DLY 92.31
- TYRA 26.16
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.